Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 10, 2019

Primary Completion Date

August 16, 2023

Study Completion Date

March 5, 2025

Conditions
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
Interventions
DRUG

Selinexor

"Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly."

Trial Locations (1)

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

University of Utah

OTHER

NCT03627403 - Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors | Biotech Hunter | Biotech Hunter